We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.
- Authors
Martinez, Shannalee R.; Elix, Catherine C.; Ochoa, Pedro T.; Sanchez-Hernandez, Evelyn S.; Alkashgari, Hossam R.; Ortiz-Hernandez, Greisha L.; Zhang, Lubo; Casiano, Carlos A.
- Abstract
Therapy resistance hinders the efficacy of anti-androgen therapies and taxane-based chemotherapy for advanced prostate cancer (PCa). Glucocorticoid receptor (GR) signaling mediates resistance to androgen receptor signaling inhibitors (ARSI) and has also been recently implicated in PCa resistance to docetaxel (DTX), suggesting a role in therapy cross-resistance. Like GR, β-catenin is upregulated in metastatic and therapy-resistant tumors and is a crucial regulator of cancer stemness and ARSI resistance. β-catenin interacts with AR to promote PCa progression. Given the structural and functional similarities between AR and GR, we hypothesized that β-catenin also interacts with GR to influence PCa stemness and chemoresistance. As expected, we observed that treatment with the glucocorticoid dexamethasone promotednuclear accumulation of GR and active β-catenin in PCa cells. Co-immunoprecipitation studies showed that GR and β-catenin interact in DTX-resistant and DTX-sensitive PCa cells. Pharmacological co-inhibition of GR and β-catenin, using the GR modulator CORT-108297 and the selective β-catenin inhibitor MSAB, enhanced cytotoxicity in DTX-resistant PCa cells grown in adherent and spheroid cultures and decreased CD44+/CD24– cell populations in tumorspheres. These results indicate that GR and β-catenin influence cell survival, stemness, and tumorsphere formation in DTX-resistant cells. Their co-inhibition could be a promising therapeutic strategy to overcome PCa therapy cross-resistance.
- Subjects
GLUCOCORTICOID receptors; ANDROGEN receptors; PROSTATE cancer; DOCETAXEL; CANCER cells; ABIRATERONE acetate; GLUCOCORTICOIDS; CELL populations
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 8, p7130
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24087130